- Home
- OXSQ vs BDTX Comparison
OXSQ vs BDTX Comparison
Compare OXSQ & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OXSQ | BDTX |
|---|---|---|
| Founded | 2003 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 151.9M | 148.1M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | OXSQ | BDTX |
|---|---|---|
| Price | $1.88 | $2.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $10.40 |
| AVG Volume (30 Days) | ★ 1.2M | 959.4K |
| Earning Date | 02-27-2026 | 03-05-2026 |
| Dividend Yield | ★ 22.58% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.38 |
| Revenue | $40,142,565.00 | ★ $70,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.27 | N/A |
| P/E Ratio | ★ N/A | $6.77 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.56 | $1.20 |
| 52 Week High | $2.87 | $4.94 |
Technical Indicators
Market Signals| Indicator | OXSQ | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 56.57 | 39.90 |
| Support Level | $1.76 | $2.56 |
| Resistance Level | $1.98 | $2.83 |
| Average True Range (ATR) | 0.05 | 0.14 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 63.64 | 32.98 |
Price Performance
Historical ComparisonAbout OXSQ Oxford Square Capital Corp.
Oxford Square Capital Corp is a closed-end, non-diversified management investment company with a focus is to seek an attractive risk-adjusted total return by investing in corporate debt securities and collateralized loan obligation (CLO) structured finance investments that own corporate debt securities. its capital is generally used by its corporate borrowers to finance organic growth, acquisitions, recapitalizations, and working capital. The group invests in various industries such as Structured Finance, IT Consulting, Business Services, Utilities, Software, Healthcare, Telecommunication Services, Plastics Manufacturing and Diversified Insurance.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.